Sensei Biotherapeutics Inc (SNSE) Stock Price, Quote & News

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-1...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.senseibio.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

FilingTracker Jun. 24 at 10:59 PM

$SNSE -> $FTH CFO purchased additional shares: https://filingtracker.ai/filing/1780030/0001780030-26-000004

0 · Reply

BearTamerTrading Jun. 24 at 6:22 PM

$GPUS $SKYQ $RCT $SNSE I don’t just alert, signal, and educate. I put my money where my alert is 😇, Part 1 of 4 Don’t forget to grab your celebration pass or BTT membership. Opportunities are here daily. Congratulations members. https://www.youtube.com/channel/UCfsmfz5F8NRG4H70oOK1CNA/join

1 · Reply

Bretm50 Jun. 24 at 4:31 PM

$SNSE Up 92% in a week, whats not to like? Room for further gains!

0 · Reply

BearTamerTrading Jun. 23 at 5:27 PM

$SNSE Another potential rocket video released last week generating profit opportunities for members. An immediate return on investments 🔥 https://www.youtube.com/live/RvTR5F1VW6w?is=TErIfu946iBF3V3g

0 · Reply

BearTamerTrading Jun. 23 at 5:26 PM

$SNSE https://www.youtube.com/live/RvTR5F1VW6w?is=TErIfu946iBF3V3g

0 · Reply

BearTamerTrading Jun. 23 at 5:25 PM

$SNSE Another potential rocket video released last week generating profit opportunities for members. https://www.youtube.com/live/RvTR5F1VW6w?is=TErIfu946iBF3V3g

1 · Reply

Stallions Jun. 23 at 2:22 PM

$SNSE Ready for Epic run

0 · Reply

YorkMeister Jun. 22 at 9:46 PM

$SNSE 55-60$ recent analyst price target

0 · Reply

aswadhama Jun. 22 at 8:29 PM

$SNSE ,I entered this one at $28.00 .I am relieved with the run today. Hoping to get break even soon and will get out of it.

0 · Reply

Stallions Jun. 22 at 7:47 PM

$SNSE Extremely Bullish. Solid phase 2 data expected. $200M cash in hand. This is going to be an EPIC stock

0 · Reply

Faeth Therapeutics initiated with an Outperform at Baird

2026-06-22T10:09:32.000Z - 3 days ago

Faeth Therapeutics initiated with a Buy at H.C. Wainwright

2026-06-18T20:05:40.000Z - 7 days ago

Faeth Therapeutics files automatic mixed securities shelf

Jun 15, 2026, 8:10 AM EDT - 10 days ago

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

Jun 4, 2026, 4:00 PM EDT - 21 days ago

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026, 7:30 AM EDT - 5 weeks ago

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026, 7:30 AM EDT - 7 weeks ago

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

Apr 9, 2026, 7:30 AM EDT - 2 months ago

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 30, 2026, 7:30 AM EDT - 3 months ago

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 18, 2026, 8:00 AM EST - 4 months ago

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Jan 7, 2026, 8:00 AM EST - 6 months ago

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

Nov 14, 2025, 7:30 AM EST - 7 months ago

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 9:00 AM EDT - 8 months ago

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Oct 17, 2025, 8:00 AM EDT - 8 months ago

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Sep 23, 2025, 7:30 AM EDT - 9 months ago

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 7:30 AM EDT - 11 months ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 7:30 AM EDT - 11 months ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jun 13, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

May 6, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 4, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 1 year ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 30, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 2 years ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 2 years ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 21, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 13, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Aug 30, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

FilingTracker Jun. 24 at 10:59 PM

$SNSE -> $FTH CFO purchased additional shares: https://filingtracker.ai/filing/1780030/0001780030-26-000004

0 · Reply

BearTamerTrading Jun. 24 at 6:22 PM

1 · Reply

Bretm50 Jun. 24 at 4:31 PM

$SNSE Up 92% in a week, whats not to like? Room for further gains!

0 · Reply

BearTamerTrading Jun. 23 at 5:27 PM

0 · Reply

BearTamerTrading Jun. 23 at 5:26 PM

$SNSE https://www.youtube.com/live/RvTR5F1VW6w?is=TErIfu946iBF3V3g

0 · Reply

BearTamerTrading Jun. 23 at 5:25 PM

$SNSE Another potential rocket video released last week generating profit opportunities for members. https://www.youtube.com/live/RvTR5F1VW6w?is=TErIfu946iBF3V3g

1 · Reply

Stallions Jun. 23 at 2:22 PM

$SNSE Ready for Epic run

0 · Reply

YorkMeister Jun. 22 at 9:46 PM

$SNSE 55-60$ recent analyst price target

0 · Reply

aswadhama Jun. 22 at 8:29 PM

$SNSE ,I entered this one at $28.00 .I am relieved with the run today. Hoping to get break even soon and will get out of it.

0 · Reply

Stallions Jun. 22 at 7:47 PM

$SNSE Extremely Bullish. Solid phase 2 data expected. $200M cash in hand. This is going to be an EPIC stock

0 · Reply

Zardiw Jun. 22 at 1:06 PM

$NWBO - #DDAmanda Chart. Showing up on the scanner. Also flagged: $AKAN $CUPR $SNSE More charts at: https://DDAmanda.com

1 · Reply

BearTamerTrading Jun. 20 at 5:19 AM

$SNSE Free Potential Rocket alert !🚨 $FTH https://www.youtube.com/live/RvTR5F1VW6w?is=Z83h4q3m8ahd9Ge5

0 · Reply

Stallions Jun. 17 at 7:33 PM

$SNSE Huge potential! This drug will be a breakthrough and will achieve new milestone in cancer treatment space. Have little more patience for phase 2 readout

0 · Reply

jrw06 Jun. 17 at 6:08 PM

$SNSE why is this board so quiet?

0 · Reply

TwongStocks Jun. 15 at 5:48 PM

$SNSE Equity Corporate Actions Alert #2026 - 409 Information Regarding the Change of Control of Sensei Biotherapeutics, Inc. (SNSE) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-409 The Change of Control of Sensei Biotherapeutics, Inc. (SNSE) was completed today, June 15, 2026. As a result, the company's Common Stock (SNSE) will undergo a corporate name and symbol change, the CUSIP will remain the same. The corporate name and ticker symbol change will become effective on June 16, 2026. Current Company Name & Symbol: Sensei Biotherapeutics, Inc. $SNSE New Company Name & Issue Type: Faeth Therapeutics, Inc. $FTH Marketplace Effective Date: June 16, 2026

0 · Reply

RTPRwire Jun. 15 at 1:11 PM

$SNSE jumped +18% the moment this crossed Business Wire: “Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer” M&A / acquisition • $13.19 at the wire Sensei Biotherapeutics changed its name to Faeth Therapeutics following its February 2026 acquisition of Faeth, with stock trading under new ticker FTH starting June 16, 2026. Get real-time catalyst alerts using RTPR.

0 · Reply

PumpyDumpty Jun. 15 at 1:00 PM

$SNSE Don't go chasing the next one! ➡️➡️➡️ QUCY Super cheap quantum play! Shorts trapped 🔥🔥

0 · Reply

Stock_Catcher Jun. 15 at 12:34 PM

$SNSE Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

0 · Reply

DARKP00L Jun. 15 at 12:24 PM

$SNSE 08:12 on Jun. 15 2026 Sensei Biotherapeutics Changes Corporate Name To Faeth Therapeutics, Ticker To FTH, Effective June 16; Appoints Anand Parikh Chairman, President And CEO; Brian Stephenson Appointed CFO, Effective June 12 #tradeideas

0 · Reply

topstockalerts Jun. 12 at 9:28 PM

$SNSE this is actually holding up way better than I thought

0 · Reply

notreload_ai Jun. 11 at 3:13 PM

Analysts initiate coverage with Buy ratings on $SNSE, $SEPN, $KZIA, $NGEN, and $STRO. https://notreload.xyz/xy/5-hot-biotech-stocks-with-fresh-buy-ratings/

0 · Reply

Kesiya Jun. 11 at 2:09 PM

$SNSE Exit

0 · Reply

Market Cap	18.59M
Revenue (ttm)	0.00
Net Income (ttm)	-21.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	219,700
Avg Vol	41,964
Day's Range	N/A - N/A
Shares Out	1.34M
Stochastic %K	39%
Beta	-0.25
Analysts	Strong Sell
Price Target	$52.50